Genes with bimodal expression are robust diagnostic targets that define distinct subtypes of epithelial ovarian cancer with different overall survival.

In some cancer types, certain genes behave as molecular switches, with on and off expression states. These genes tend to define tumor subtypes associated with different treatments and different patient survival. We hypothesized that clinically relevant molecular switch genes exist in epithelial ovarian cancer. To test this hypothesis, we applied a bimodal discovery algorithm to a publicly available ovarian cancer expression microarray data set, GSE9891 [285 tumors: 246 malignant serous (MS), 20 endometrioid (EM), and 18 low malignant potential (LMP) ovarian carcinomas]. Genes with robust bimodal expression patterns were identified across all ovarian tumor types and also within selected subtypes: 73 bimodal genes demonstrated differential expression between LMP versus MS and EM; 22 bimodal genes distinguished MS from EM; and 14 genes had significant association with survival among MS tumors. When these genes were combined into a single survival score, the median survival for patients with a favorable versus unfavorable score was 65 versus 29 months (P < 0.0001, hazard ratio = 0.4221). Two independent data sets [high-grade, advanced-stage serous (n = 53) and advanced-stage (n = 119) ovarian tumors] validated the survival score performance. We conclude that genes with bimodal expression patterns not only define clinically relevant molecular subtypes of ovarian carcinoma but also provide ideal targets for translation into the clinical laboratory.

[1]  J. Herman,et al.  Prognostic significance of Gremlin1 (GREM1) promoter CpG island hypermethylation in clear cell renal cell carcinoma. , 2010, The American journal of pathology.

[2]  Arie Perry,et al.  Identification of Gene Markers Associated With Aggressive Meningioma by Filtering Across Multiple Sets of Gene Expression Arrays , 2011, Journal of neuropathology and experimental neurology.

[3]  Marie Joseph,et al.  Gene expression signature with independent prognostic significance in epithelial ovarian cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Gabriele Schackert,et al.  Highly specific overexpression of the transcription factor SOX11 in human malignant gliomas. , 2005, Oncology reports.

[5]  M. Wegner,et al.  Cooperative Function of POU Proteins and SOX Proteins in Glial Cells* , 1998, The Journal of Biological Chemistry.

[6]  H. Hollema,et al.  Survival-Related Profile, Pathways, and Transcription Factors in Ovarian Cancer , 2009, PLoS medicine.

[7]  Maurice P H M Jansen,et al.  Molecular profiling of platinum resistant ovarian cancer , 2006, International journal of cancer.

[8]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[9]  B. Taillon,et al.  Second Generation Sequencing of the Mesothelioma Tumor Genome , 2010, PloS one.

[10]  R. Tothill,et al.  Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome , 2008, Clinical Cancer Research.

[11]  W. Wong,et al.  A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. , 2009, Cancer cell.

[12]  Wing H Wong,et al.  Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. , 2005, Cancer research.

[13]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[14]  Anders Bjartell,et al.  Evaluation of the prognostic significance of MSMB and CRISP3 in prostate cancer using automated image analysis , 2011, Modern Pathology.

[15]  A. Rosenwald,et al.  Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. , 2010, Cancer research.

[16]  R. Agarwal,et al.  Prognostic factors in ovarian cancer: how close are we to a complete picture? , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  Jeffrey T. Chang,et al.  Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.

[18]  Sami Kilpinen,et al.  The transcription factor Sox11 is a prognostic factor for improved recurrence-free survival in epithelial ovarian cancer. , 2009, European journal of cancer.

[19]  Ituro Inoue,et al.  Gene Expression Profile for Predicting Survival in Advanced-Stage Serous Ovarian Cancer Across Two Independent Datasets , 2010, PloS one.

[20]  Kevin R. Coombes,et al.  The Bimodality Index: A Criterion for Discovering and Ranking Bimodal Signatures from Cancer Gene Expression Profiling Data , 2009, Cancer informatics.

[21]  P. Neven,et al.  Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. West,et al.  Patterns of Gene Expression That Characterize Long-term Survival in Advanced Stage Serous Ovarian Cancers , 2005, Clinical Cancer Research.

[23]  L. Feuk,et al.  Detection of large-scale variation in the human genome , 2004, Nature Genetics.

[24]  A. Ashworth,et al.  Breast cancer molecular profiling with single sample predictors: a retrospective analysis. , 2010, The Lancet. Oncology.

[25]  Alok J. Saldanha,et al.  Java Treeview - extensible visualization of microarray data , 2004, Bioinform..

[26]  Trevor Hastie,et al.  Gene expression patterns in ovarian carcinomas. , 2003, Molecular biology of the cell.

[27]  Javed Khan,et al.  Gene Expression Profiles Associated with Response to Chemotherapy in Epithelial Ovarian Cancers , 2005, Clinical Cancer Research.

[28]  D G Altman,et al.  A prognostic model for ovarian cancer , 2001, British Journal of Cancer.

[29]  Kathleen R. Cho,et al.  Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. , 2002, Cancer research.

[30]  W. Gerald,et al.  Association of Cysteine-Rich Secretory Protein 3 and β-Microseminoprotein with Outcome after Radical Prostatectomy , 2007, Clinical Cancer Research.

[31]  B. Sander,et al.  The subcellular Sox11 distribution pattern identifies subsets of mantle cell lymphoma: correlation to overall survival , 2008, British journal of haematology.

[32]  C. Le Page,et al.  BMP-2 signaling in ovarian cancer and its association with poor prognosis , 2009, Journal of ovarian research.

[33]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[34]  D. Metzler,et al.  Data driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer , 2010, Breast Cancer Research and Treatment.

[35]  David I. Smith,et al.  Gene Expression Profiles Predict Early Relapse in Ovarian Cancer after Platinum-Paclitaxel Chemotherapy , 2005, Clinical Cancer Research.

[36]  C. Arteaga,et al.  New Strategies in HER2-Overexpressing Breast Cancer: Many Combinations of Targeted Drugs Available , 2011, Clinical Cancer Research.

[37]  D. Lockhart,et al.  Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[38]  M. van de Rijn,et al.  Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. , 2005, Gynecologic oncology.

[39]  W. Weichert,et al.  A prognostic gene expression index in ovarian cancer—validation across different independent data sets , 2009, The Journal of pathology.